BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Felix T, Jordan JB, Akers C, Patel B, Drago D. Current state of biologic pharmacovigilance in the European Union: improvements are needed. Expert Opinion on Drug Safety 2019;18:231-40. [DOI: 10.1080/14740338.2019.1577818] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Mlotshwa CR, Burger JR, Vorster M, Rakumakoe DM, Cockeran M. Completeness of pharmaceutical industry insulin adverse event reports from Africa and the Middle East. Expert Opin Drug Saf 2022. [PMID: 35946933 DOI: 10.1080/14740338.2022.2110863] [Reference Citation Analysis]
2 Correia Pinheiro L, Giezen TJ, Wolff-Holz E, Weise M, Laslop A, Hidalgo-Simon A. Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions. Clin Pharmacol Ther 2021;110:1311-7. [PMID: 34472087 DOI: 10.1002/cpt.2411] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Afzali A, Furtner D, Melsheimer R, Molloy PJ. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable. Adv Ther 2021;38:2077-93. [PMID: 33745111 DOI: 10.1007/s12325-021-01688-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Iannone LF, Bennardo L, Palleria C, Roberti R, De Sarro C, Naturale MD, Dastoli S, Donato L, Manti A, Valenti G, D'Amico D, D'Attola S, De Francesco AE, Bosco V, Donato Di Paola E, Nisticò SP, Citraro R, Russo E, De Sarro G. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. PLoS One 2020;15:e0241575. [PMID: 33141869 DOI: 10.1371/journal.pone.0241575] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
5 Rodríguez S, Muñoz A, Bustos RH, Jaimes D. Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview. Biomedicines 2020;8:E303. [PMID: 32842558 DOI: 10.3390/biomedicines8090303] [Reference Citation Analysis]
6 Alshammari TM, Alenzi KA, Ata SI. National pharmacovigilance programs in Arab countries: A quantitative assessment study. Pharmacoepidemiol Drug Saf 2020;29:1001-10. [PMID: 32181540 DOI: 10.1002/pds.4991] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ferreira Neto PTP, Nunes PHC, Vargas MA. [Interchangeability of biological products in the Brazilian Unified National Health System (SUS): the main regulatory challenges]. Cad Saude Publica 2019;35:e00053519. [PMID: 31618379 DOI: 10.1590/0102-311X00053519] [Reference Citation Analysis]
8 Oza B, Radhakrishna S, Pipalava P, Jose V. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics? J Postgrad Med 2019;65:227-32. [PMID: 31571620 DOI: 10.4103/jpgm.JPGM_109_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]